PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1803452

[IgA glomerulonephritis].

E Alamartine·F Berthoux
View original source ↗Export metadata ↓

Abstract

Primary IgA nephritis is the most frequent nephritis and represent half of the glomerular diseases. Its incidence is 2,7/10(5) inhabitants. The diagnosis is established on a renal biopsy, which shows typical IgA mesangial deposits: granular, predominant, and diffuse. A central pathogenic role is played by the IgA immune system, both from the mucosa and the bone marrow. The long term prognosis should no longer be considered as mild because, after 20 years of evolution, 1/3 of the patients are going into chronic renal failure, and 1/6 into end-stage renal disease. It is essential to delineate the risk factors predicting ultimate evolution towards chronic failure, to select patients who may benefit from aggressive treatment, such as high doses steroids. For all patients, it is essential to have a regular clinical and biological check up, and an adequate control of arterial hypertension, in order to avoid or delay progression.

Explore related subjects

Glomerulonephritis, IGAHumansIgA VasculitisLiver Cirrhosis, AlcoholicJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Alamartine, F Berthoux. 1991-11-15. [IgA glomerulonephritis].. https://pubmed.ncbi.nlm.nih.gov/1803452/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Binding capacity of in vitro deglycosylated IgA1 to human mesangial cells.

IgA nephropathy (IgAN) is the most common glomerular disease and it is characterized by deposition of IgA1 molecules in mesangium. Recent studies had demonstrated that serum and mesangial IgA1 in IgAN were deglycosylated and IgA1 could bind to human mesangial cells (HMC) through a novel receptor. The aim of the current study is to investigate and compare the binding capacities of different in vitro deglycosylated IgA1 on human mesangial cells. Serum IgA1 was purified by jacalin affinity chromatography and then was desialylated (DesIgA1) and/or degalactosylated (Des/DeGalIgA1) with neuraminidase and/or beta-galactosidase. The efficacy of deglycosylations was assessed by Peanut agglutinin (PNA) and Vicia villosa (VV) lectin. The sizes of normal IgA1 and deglycosylated IgA1 were determined by Sephacryl S-300 chromatography and binding capacities to primary HMC were evaluated by radioligand binding assays. Normal IgA1 and deglycosylated IgA1 could bind to HMC in a dose-dependent, saturable manner. The maximal binding capacities and binding sites/cell of DesIgA1 and Des/DeGalIgA were significantly higher than that of normal IgA1. However, more aggregated IgA1 was found in DesIgA1 and Des/DeGalIgA1. Scatchard analysis revealed a similar Kd of normal IgA1 and deglycosylated IgA1. The current study suggested that the binding capacities of DesIgA1 and Des/DeGalIgA1 to HMC were significantly higher than that of normal IgA1, which at least in part was due to more macromolecular IgA1 in deglycoslated IgA1. However, there were no significant differences in the affinities of normal IgA1, DesIgA1 and Des/DeGalIgA1 with HMC. Deglycosylated IgA1 might play an important role in pathogenesis of IgAN.

Glomerulonephritis, IGA↗
PubMed2006

The IgA nephropathy treatment dilemma.

Although IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, our understanding of the pathogenesis of this complex disease remains limited. IgA nephropathy may appear with a variety of clinical presentations, a number of different clinical and histopathologic risk factors for progressive renal disease, and a very variable course over time. Thus, it is not surprising that a single therapeutic treatment plan has not been established. Many of the studies dealing with IgAN are retrospective, lack statistical significance, or have confounding designs, which hinder their general acceptance. Nevertheless, a number of well-designed studies have been performed. This paper reviews currently available therapeutic options for IgAN. It attempts to address several important questions: Why do we treat patients with IgAN? How do we decide which patients should be treated? What are the general treatment guidelines for all IgAN patients? What is the role of specific therapy such as fish oils, tonsillectomy, and immunosuppression in the treatment of patient with IgAN? It also addresses several on-going trials and goals for future therapeutic studies for IgAN patients.

Glomerulonephritis, IGA↗